Melphalan in the Treatment of Myelomatosis
Melphalan in the Treatment of Myelomatosis
复制标题
马法兰治疗骨髓瘤病
DOI：
10.1136/bmj.1.5399.1664
复制
发表时间：
1964
影响因子：
--
通讯作者：
A. Swan
中科院分区：
文献类型：
--
作者：
D. Speed;D. Galton;A. Swan
本文报道了melphalan （p-二-（2-氯乙基）氨基- l -苯丙氨酸）33个月的试验结果；“Alkeran”)治疗骨髓瘤病。这种芳香氮芥是由Bergel和Stock（1953）合成的。外消旋形式merphalan（肌溶素）是在莫斯科合成的（Larionov, Khokhlov, Shkodinskaja, Vasina, Troosheikina, and Novikova, 1955）。该试验于1959年12月开始，在该日至1962年3月1日期间首次治疗了20名患者。本报告包括截至1962年9月1日的观察结果，当时有7名病人死亡。因此，最短的随访时间为6个月。其他地方也报告了3例（第2、3和13号）（Swan, 1962）。表1显示了患者的年龄和性别，诊断时间到美法仑开始治疗的时间间隔，之前接受的治疗，每位患者在美法仑开始治疗后的观察时间，以及服用美法仑的疗程数。5例患者在开始美法仑治疗前不到一年就确诊，7例患者在1至2年之间确诊，8例患者在2至6年和3 / 4年之间确诊。2例患者只用了1个疗程，7例患者只用了2 ~ 5个疗程，10例患者只用了6 ~ 12个疗程，1例患者只用了19个疗程。1例接受美法兰治疗的患者观察了两年半，6例治疗了12至18个月，13例治疗了不到一年。7名患者此前未接受过骨髓瘤病治疗，8名患者接受过局部x线治疗以缓解疼痛。三个
This paper reports the results of 33 months' trial of melphalan (p-di-(2-chloroethyl)amino-L-phenylalanine; " alkeran ") in the treatment of myelomatosis. This aromatic nitrogen mustard was synthesized by Bergel and Stock (1953). The racemic form, merphalan (sarcolysin), was synthesized in Moscow (Larionov, Khokhlov, Shkodinskaja, Vasina, Troosheikina, and Novikova, 1955). The trial started in December 1959, and 20 patients were first treated between that date and 1 March 1962. This report includes observations made up to 1 September 1962, when seven patients had died. The shortest possible period of follow-up was thus six months. Three cases (Nos. 2, 3, and 13) have been reported elsewhere (Swan, 1962). Table I shows the age and sex of the patients, the interval between the time of diagnosis and the start of melphalan therapy, the previous treatment received, the duration of observation of each patient after the start of melphalan therapy, and the number of courses of melphalan administered. The diagnosis had been established less than one year before the start of melphalan therapy in five cases, between one and two years in seven, and between two and six and three quarter years in eight. Two patients received only one course of melphalan, seven received two to five courses, 10 received 6 to 12 courses, and one received 19. One patient receiving melphalan was observed for two and a half years, six were treated for 12 to 18 months, and 13 for less than one year. Seven patients had had no previous treatment for myelomatosis, while eight had received local x-ray therapy for the relief of pain. Three of